The revised CONSORT statement for reporting randomized trials: Explanation and elaboration

Annals of Internal Medicine

Volumn 134, Issue 8, 2001, Pages 663-694

  Lepage, L ^a   Altman, D G ^a   Schulz, K F ^a   Moher, D ^a   Egger, M ^a   Davidoff, F ^a   Elbourne, D ^a   Gotzsche P C ^a   Lang, T ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CLINICAL RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; INFORMATION PROCESSING; INTERNET; MEDICAL ETHICS; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; STANDARD;

EID: 0035901579     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-8-200104170-00012     Document Type: Review

References (204)

1. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
2. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials
3. Quality of randomised clinical trials affects estimates of intervention efficacy
4. Assessing the quality of controlled clinical trials
5. Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials
6. Psychological treatments for irritable bowel syndrome: A critique of controlled treatment trials
7. How well are randomized controlled trials reported in the dermatology literature?
8. Randomized clinical trials in HEPATOLOGY: Predictors of quality
9. Statistical evaluation of medical journal manuscripts
10. Misuse of statistical methods: Critical assessment of articles in BMJ from January to March 1976
11. Misuse of statistical methods in the Australasian surgical literature
12. Statistics in medical journals
13. Statistical problems in the reporting of clinical trials. A survey of three medical journals
14. The scandal of poor medical research
15. Reporting on methods in clinical trials
16. Statistical power, sample size, and their reporting in randomized controlled trials
17. What is meant by intention to treat analysis? Survey of published randomised controlled trials
18. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis
19. The quality of clinical trials punished in The Journal of Family Practice, 1974-1991
20. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals
21. Randomised trials, human nature, and reporting guidelines
22. A qualitative assessment of randomized controlled trials in otolaryngology
23. Quality of full and final publications reporting acute stroke trials: A systematic review
24. Randomisation and baseline comparisons in clinical trials
25. Reporting of assignment methods in clinical trials
26. Reporting standards and research strategies for controlled trials. Agenda for the editor
27. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis
28. An evaluation of the quality of therapeutic studies in perinatal medicine
29. Completeness of reporting of trials published in languages other than English: Implications for conduct and reporting of systematic reviews
30. Adherence to published standards of reporting: A comparison of placebo-controlled trials published in English or German
31. Randomisation
32. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation
33. Randomized controlled trials
34. The role of randomization in clinical trials
35. Randomization, statistics, and causal inference
36. So what's so special about randomisation
37. Assembling comparison groups to assess the effects of health care
38. Content and quality of 2000 controlled trials in schizophrenia over 50 years
39. A proposal for structured reporting of randomized controlled trials
40. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature
41. Reporting randomized controlled trials. An experiment and a call for responses from readers
42. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
43. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine
44. Guidelines for authors and peer reviewers of economic submissions to the BMJ
45. Guidelines for reporting results of quality of life assessments in clinical trials
46. Better reporting of randomised controlled trials: The CONSORT statement
47. A standard method for reporting randomized medical scientific research; the 'Consolidation of the standards of reporting trials'
48. CMAJ endorses the CONSORT statement. CONsolidation of Standards for Reporting Trials
49. CONSORT: An attempt to improve the quality of publication of clinical trials
50. News from the International Committee of Medical Journal Editors
51. Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation
52. Value of flow diagrams in reports of randomized controlled trials
53. Beyond CONSORT: Need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials
54. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials
55. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials
56. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomised trials
57. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety
58. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial
59. Identifying relevant studies for systematic reviews
60. Identifying randomised trials
61. More informative abstracts revisited
62. Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association
63. Obtaining information accurately and quickly: Are structured abstracts more efficient?
64. Injection with methylprednisolone proximal to the carpal tunnel: Randomised double blind trial
65. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder
66. Recommendations guiding physicians in biomedical research involving human subjects
67. Cumulative meta-analysis of therapeutic trials for myocardial infarction
68. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability
69. Preventing IUCD-related pelvic infection: The efficacy of prophylactic doxycycline at insertion
70. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: Implications for the interpretation and design of thromboprophylaxis trials
71. A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program
72. Methodologic standards in surgical trials
73. Reporting the study populations of clinical trials. Clear transmission or static on the line?
74. Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series
75. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
76. The implications of variation in outcome between health professionals for the design and analysis of randomized controlled trials
77. A randomised controlled trial and meta-analysis of active management of labour
78. Reporting on quality of life in randomised controlled trials: Bibliographic study
79. Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia
80. Treatment of attention-deficit/hyperactivity disorder
81. 6/L CD4 cell counts: A randomized controlled trial
82. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
83. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial
84. Costs and effectiveness of community postnatal support workers: Randomised controlled trial
85. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons
86. Absence of evidence is not evidence of absence
87. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials
88. Why do we need some large, simple randomized trials?
89. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results
90. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study
91. Comparison of oral fluconazole and itraconazole for progressive, non-meningeal coccidioidomycosis. A randomized, double-blind trial
92. Interim analyses in randomized clinical trials: Ramifications and guidelines for practitioners
93. Interim analyses in clinical trials: Classical vs. Bayesian approaches
94. When to stop a clinical trial
95. The agonising negative trend in monitoring of clinical trials
96. Interim analyses, stopping rules and data monitoring in clinical trials in Europe
97. How to randomise
98. Subverting randomization in controlled trials
99. Baseline comparability in clinical trials
100. Minimisation: The platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does
101. Stratified randomization for clinical trials
102. Adjustment of treatment effect for covariates in clinical trials: Statistical and regulatory issues
103. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial
104. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials
105. Statistical aspects of clinical trial design
106. Technologies for automating randomized treatment assignment in clinical trials
107. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial
108. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial
109. Blinding during data analysis and writing of manuscripts
110. An open prospective randomised trial to reduce the pain of blood glucose testing: Ear versus thumb
111. Statistics notes: Blinding in clinical trials and other studies
112. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials
113. Blinding and exclusions after allocation in randomised controlled trials: Survey of published parallel group trials in obstetrics and gynaecology
114. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention
115. Masking or blinding? An unscientific survey of mostly medical journal editors on the great debate
116. Evaluation of acupuncture for pain control after oral surgery: A placebo-controlled trial
117. Validity of clinical trials of antidepressants
118. Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia
119. Statistical guidelines for contributors to medical journals
120. Statistics notes. Units of analysis
121. Independence and statistical inference in clinical trial designs: A tutorial review
122. Principles of multilevel modelling
123. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial
124. Interaction 3: How to examine heterogeneity
125. Subgroup analysis and other (mis)uses of baseline data in clinical trials
126. Statistics notes. Interaction 2: Compare effect sizes not P values
127. A consumer's guide to subgroup analyses
128. Clinical trials in acute myocardial infarction: Should we adjust for baseline characteristics?
129. Adjustment for covariate imbalance
130. The risk of determining risk with multivariable models
131. Logistic regression models used in medical research are poorly presented
132. Logistic regression models in obstetrics and gynecology literature
133. Controversy in counting and attributing events in clinical trials
134. The randomized clinical trial: Bias in analysis
135. More on zidovudine in asymptomatic HIV infection
136. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
137. Spinal manipulation in the treatment of episodic tension-type headache: A randomized controlled trial
138. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
139. Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term
140. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
141. Median follow-up in clinical trials
142. Review of survival analyses published in cancer journals
143. Base logic: Tests of baseline balance in randomized clinical trials
144. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease
145. Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions
146. Analysis of clinical trials by treatment actually received: Is it really an option?
147. Intention to treat - Who should use ITT?
148. Statistical considerations in the intent-to-treat principle
149. Intention-to-treat analysis and the goals of clinical trials
150. Estimating treatment effects in randomized clinical trials in the presence of non-compliance
151. Intention to treat analysis is related to methodological quality
152. Confidence intervals in practice
153. Clinical trials and meta-analyses
154. Uniform requirements for manuscripts submitted to biomedical journals
155. Confidence intervals rather than P values: Estimation rather than hypothesis testing
156. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations
157. Bias in meta-analysis due to outcome variable selection within studies
158. Problems and limitations in conducting systematic reviews
159. Quoting intermediate analyses can only mislead
160. The number needed to treat: A clinically useful measure of treatment effect
161. Calculating the number needed to treat for trials where the outcome is time to an event
162. Some thoughts on clinical trials, especially problems of multiplicity
163. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
164. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies
165. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
166. Completeness of safety reporting in randomized trials. An evaluation of 7 medical areas
167. The rhetoric of research
168. The case for structuring the discussion of scientific papers
169. Changes to manuscripts during the editorial process: Characterizing the evolution of a clinical paper
170. Randomized trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis
171. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
172. Factors relevant to the validity of experiments in social settings
173. Assessing the quality of controlled clinical trials
174. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient
175. Who benefits from medical interventions?
176. Applying the results of systematic reviews at the bedside
177. An assessment of clinically useful measures of the consequences of treatment
178. Confidence intervals for the number needed to treat
179. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network
180. Randomized trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1
181. Somatostatin v placebo in bleeding oesophageal varices: Randomised trial and meta-analysis
182. Discussion sections in reports of controlled trials published in general medical journals: Islands in search of continents?
183. Toward evidence-based medical statistics. 1: The P value fallacy
184. Reference bias in reports of drug trials
185. An assessment of publication bias using a sample of published clinical trials
186. Randomized trials versus observational studies in adolescent pregnancy prevention
187. The unpredictability paradox: Review of empirical comparisons of randomised and non-randomised clinical trials
188. A comparison of observational studies and randomized, controlled trials
189. Randomized, controlled trials, observational studies, and the hierarchy of research designs
190. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials
191. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
192. Promoting good research practice
193. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses
194. Meta-analysis of observational studies in epidemiology: A proposal for reporting